Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in Canada
TORONTO and CHICAGO and WEDEL, Germany, July 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company orMedexus) (TSX: MDP) (OTCQX: MEDXF) today announced that it has entered into a licensing agreement, formalizing its relationship with medac GmbH (medac) to commercialize treosulfan, a bifunctional alkylating agent, in Canada.
- TORONTO and CHICAGO and WEDEL, Germany, July 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company orMedexus) (TSX: MDP) (OTCQX: MEDXF) today announced that it has entered into a licensing agreement, formalizing its relationship with medac GmbH (medac) to commercialize treosulfan, a bifunctional alkylating agent, in Canada.
- Michael Pine, Senior Vice President of Business Development and Strategy, commented, We are pleased to have signed our third licensing agreement with medac and to expand our strong collaboration.
- medac GmbH is a privately held, global pharmaceutical company with a growing pharmaceutical and diagnostics business.
- Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy.